| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/BIOT.201600243 |
| P698 | PubMed publication ID | 28296342 |
| P2093 | author name string | Cui-Tao Lu | |
| Ying-Zheng Zhao | |||
| Xiao-Kun Li | |||
| He-Lin Xu | |||
| Wen-Ze Yu | |||
| P2860 | cites work | Efficacy of photocrosslinkable chitosan hydrogel containing fibroblast growth factor-2 in a rabbit model of chronic myocardial infarction | Q46510216 |
| Dual growth factor-induced angiogenesis in vivo using hyaluronan hydrogel implants | Q46771796 | ||
| Biodegradation and heart retention of polymeric microparticles in a rat model of myocardial ischemia | Q46865029 | ||
| Preferential accumulation and export of high molecular weight FGF-2 by rat cardiac non-myocytes | Q47420022 | ||
| Enhancing efficacy of stem cell transplantation to the heart with a PEGylated fibrin biomatrix | Q47710993 | ||
| Tracking the in vivo release of bioactive NRG from PLGA and PEG-PLGA microparticles in infarcted hearts. | Q48643281 | ||
| Adipose-derived stromal cells mediate in vivo adipogenesis, angiogenesis and inflammation in decellularized adipose tissue bioscaffolds | Q48652312 | ||
| Therapeutic Angiogenesis With Intramuscular NV1FGF Improves Amputation-free Survival in Patients With Critical Limb Ischemia | Q49025617 | ||
| Promotion of cardiac differentiation of brown adipose derived stem cells by chitosan hydrogel for repair after myocardial infarction. | Q50479536 | ||
| Treatment of reperfused ischemia with adipose-derived stem cells in a preclinical Swine model of myocardial infarction. | Q50498609 | ||
| Cardioprotective effects of transforming growth factor-beta1 during early reoxygenation or reperfusion are mediated by p42/p44 MAPK. | Q50502764 | ||
| Regulation of sequential release of growth factors using bilayer polymeric nanoparticles for cardiac tissue engineering. | Q50547397 | ||
| Controlled release of bioactive PDGF-AA from a hydrogel/nanoparticle composite. | Q50947762 | ||
| Controlled release of stromal cell-derived factor-1 alpha in situ increases c-kit+ cell homing to the infarcted heart. | Q50998107 | ||
| Controlled delivery of fibroblast growth factor-1 and neuregulin-1 from biodegradable microparticles promotes cardiac repair in a rat myocardial infarction model through activation of endogenous regeneration. | Q51187107 | ||
| Entrapment of basic fibroblast growth factor (bFGF) in a succinylated chitosan nanoparticle delivery system and release profile. | Q51345198 | ||
| Spontaneous Coassembly of Biologically Active Nanoparticles via Affinity Binding of Heparin-Binding Proteins to Alginate-Sulfate. | Q51570069 | ||
| Factors affecting the viscosity in high concentration solutions of different monoclonal antibodies. | Q51663592 | ||
| Accelerated wound closure of pressure ulcers in aged mice by chitosan scaffolds with and without bFGF. | Q51738631 | ||
| Coordinated induction of cell survival signaling in the inflamed microenvironment of the prostate. | Q52874494 | ||
| Pre-treatment of mesenchymal stem cells with a combination of growth factors enhances gap junction formation, cytoprotective effect on cardiomyocytes, and therapeutic efficacy for myocardial infarction. | Q53547964 | ||
| The Effect of EPO Gene Overexpression on Proliferation and Migration of Mouse Bone Marrow-Derived Mesenchymal Stem Cells. | Q54309775 | ||
| Essential role of endothelial nitric oxide synthase for mobilization of stem and progenitor cells | Q58816342 | ||
| Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. | Q26782024 | ||
| Long-term delivery of protein therapeutics | Q26860505 | ||
| Stem cells as drug delivery methods: application of stem cell secretome for regeneration | Q26862657 | ||
| The interaction between thermodynamic stability and buried free cysteines in regulating the functional half-life of fibroblast growth factor-1 | Q27657105 | ||
| Fibroblast growth factors as multifunctional signaling factors | Q28283514 | ||
| Novel therapy for myocardial infarction: can HGF/Met be beneficial? | Q28305555 | ||
| Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1 | Q28513759 | ||
| VEGF receptor signalling - in control of vascular function | Q29617256 | ||
| Intracoronary cardiosphere-derived cells for heart regeneration after myocardial infarction (CADUCEUS): a prospective, randomised phase 1 trial | Q29620043 | ||
| Targets and delivery methods for therapeutic angiogenesis in peripheral artery disease | Q30449821 | ||
| High molecular weight fibroblast growth factor-2 in the human heart is a potential target for prevention of cardiac remodeling | Q31161236 | ||
| Platelet-derived growth factor-AB promotes the generation of adult bone marrow-derived cardiac myocytes | Q33198269 | ||
| Sustained vascular endothelial growth factor delivery enhances angiogenesis and perfusion in ischemic hind limb | Q33219845 | ||
| Results of a double-blind, placebo-controlled study to assess the safety of intramuscular injection of hepatocyte growth factor plasmid to improve limb perfusion in patients with critical limb ischemia | Q33344368 | ||
| Controlled angiogenesis in the heart by cell-based expression of specific vascular endothelial growth factor levels | Q33586957 | ||
| Assessment and optimization of cell engraftment after transplantation into the heart | Q33680007 | ||
| The promotion of myocardial repair by the sequential delivery of IGF-1 and HGF from an injectable alginate biomaterial in a model of acute myocardial infarction | Q33708539 | ||
| "Click" immobilization of a VEGF-mimetic peptide on decellularized endothelial extracellular matrix to enhance angiogenesis. | Q33761789 | ||
| Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization | Q33870103 | ||
| Cardiac progenitor cells and biotinylated insulin-like growth factor-1 nanofibers improve endogenous and exogenous myocardial regeneration after infarction | Q34032940 | ||
| Safety and efficacy of an injectable extracellular matrix hydrogel for treating myocardial infarction | Q34035670 | ||
| Concise review: injectable biomaterials for the treatment of myocardial infarction and peripheral artery disease: translational challenges and progress | Q34109419 | ||
| The use of magnetic resonance cell tracking to monitor endothelial progenitor cells in a rat hindlimb ischemic model | Q34113993 | ||
| Hepatocyte growth factor effects on mesenchymal stem cells: proliferation, migration, and differentiation | Q34442918 | ||
| Fibroblast growth factors: biology, function, and application for tissue regeneration | Q34591107 | ||
| Biological activities of fibroblast growth factor-2 in the adult myocardium | Q35035307 | ||
| The role of TGFβ1 and LRG1 in cardiac remodelling and heart failure. | Q35065245 | ||
| Translation of PDGF cardioprotective pathways | Q35096095 | ||
| Transplantation of ex vivo expanded endothelial progenitor cells for therapeutic neovascularization | Q35111623 | ||
| Design properties of hydrogel tissue-engineering scaffolds | Q35503173 | ||
| Sustained release of VEGF from PLGA nanoparticles embedded thermo-sensitive hydrogel in full-thickness porcine bladder acellular matrix. | Q35536972 | ||
| Use of human embryonic stem cell derived-mesenchymal cells for cardiac repair | Q35563408 | ||
| Biomaterial strategies for alleviation of myocardial infarction | Q35571962 | ||
| Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies | Q35684362 | ||
| Mesenchymal stem cells and their potential as cardiac therapeutics | Q35830869 | ||
| Vascular endothelial growth factor and angiogenesis | Q35985850 | ||
| The use of injectable sonication-induced silk hydrogel for VEGF(165) and BMP-2 delivery for elevation of the maxillary sinus floor | Q36062757 | ||
| Mechanism of the cardioprotective effect of transforming growth factor beta 1 in feline myocardial ischemia and reperfusion | Q36086349 | ||
| Administration of cardiac stem cells in patients with ischemic cardiomyopathy: the SCIPIO trial: surgical aspects and interim analysis of myocardial function and viability by magnetic resonance | Q36252910 | ||
| Mechanism of action and delivery possibilities for TGFbeta1 in the treatment of myocardial ischemia | Q36748667 | ||
| TGF-beta signaling in vascular fibrosis. | Q36765987 | ||
| Apoptosis and the cardiac action of insulin-like growth factor I. | Q36820792 | ||
| Fibroblast growth factor-2 and cardioprotection | Q36827900 | ||
| Stem-cell therapy for cardiac disease | Q37089732 | ||
| Neuregulin in cardiovascular development and disease | Q37118330 | ||
| Therapeutic angiogenesis: a new treatment approach for ischemic heart disease--part I. | Q37194301 | ||
| Novel polymer carriers and gene constructs for treatment of myocardial ischemia and infarction | Q37228936 | ||
| Improving outcome of transplanted mesenchymal stem cells for ischemic heart disease | Q37267917 | ||
| Restored perfusion and reduced inflammation in the infarcted heart after grafting stem cells with a hyaluronan-based scaffold | Q37294128 | ||
| Cytokines and myocardial regeneration: a novel treatment option for acute myocardial infarction | Q37353653 | ||
| PDGF mediates cardiac microvascular communication | Q37384601 | ||
| Human studies of angiogenic gene therapy | Q37406656 | ||
| Role of interleukins, IGF and stem cells in BPH | Q37416239 | ||
| Thermo-sensitive hydrogels combined with decellularised matrix deliver bFGF for the functional recovery of rats after a spinal cord injury | Q37475895 | ||
| Impact of timing on efficacy and safetyof intracoronary autologous bone marrow stem cells transplantation in acute myocardial infarction: a pooled subgroup analysis of randomized controlled trials | Q37580861 | ||
| Protein therapeutics for cardiac regeneration after myocardial infarction | Q37770453 | ||
| Stem cell engraftment and survival in the ischemic heart. | Q37940059 | ||
| TGF-β1 regulates differentiation of bone marrow mesenchymal stem cells | Q37962752 | ||
| Hydrogels for protein delivery in tissue engineering. | Q37994007 | ||
| Role of SDF1/CXCR4 interaction in experimental hemiplegic models with neural cell transplantation | Q38001423 | ||
| Silk fibroin biomaterials for tissue regenerations | Q38058637 | ||
| Injectable hydrogel therapies and their delivery strategies for treating myocardial infarction | Q38058891 | ||
| Poly(ethylene glycol)-poly(lactic-co-glycolic acid) based thermosensitive injectable hydrogels for biomedical applications | Q38154399 | ||
| Strategies affording prevascularized cell-based constructs for myocardial tissue engineering | Q38186710 | ||
| Drug and cell delivery for cardiac regeneration. | Q38244791 | ||
| The role of hyaluronan in tumour neovascularization (review). | Q38297939 | ||
| Therapeutic angiogenesis for critical limb ischemia | Q38392203 | ||
| Hydrogels for therapeutic cardiovascular angiogenesis | Q38554654 | ||
| Therapeutic uses of FGFs | Q38586578 | ||
| Smart Nanoscale Drug Delivery Platforms from Stimuli-Responsive Polymers and Liposomes. | Q38626956 | ||
| Hepatocyte growth factor (HGF) and hemodialysis: physiopathology and clinical implications | Q38671668 | ||
| Magnetic field-responsive release of transforming growth factor beta 1 from heparin-modified alginate ferrogels | Q38754702 | ||
| Stability and degradation of fibroblast growth factor 23 (FGF23): the effect of time and temperature and assay type | Q38901793 | ||
| Adipose-derived stem cells combined with neuregulin-1 delivery systems for heart tissue engineering | Q39108275 | ||
| PEGylated-PLGA microparticles containing VEGF for long term drug delivery. | Q39311713 | ||
| Differential effect of hypoxia on early endothelial-mesenchymal transition response to transforming growth beta isoforms 1 and 2. | Q39509758 | ||
| Photocrosslinkable hydrogel for myocyte cell culture and injection. | Q40232658 | ||
| VEGF165 and angiopoietin-1 decreased myocardium infarct size through phosphatidylinositol-3 kinase and Bcl-2 pathways. | Q40472491 | ||
| Myocardial protection from ischemia/reperfusion injury by endogenous and exogenous HGF. | Q40761395 | ||
| Overview of the fibroblast growth factor and receptor families: complexity, functional diversity, and implications for future cardiovascular research | Q40786557 | ||
| VEGF-Loaded Nanoparticle-Modified BAMAs Enhance Angiogenesis and Inhibit Graft Shrinkage in Tissue-Engineered Bladder | Q41358222 | ||
| Characterization and assessment of hyperelastic and elastic properties of decellularized human adipose tissues | Q41759584 | ||
| Safety evaluation of clinical gene therapy using hepatocyte growth factor to treat peripheral arterial disease | Q42630861 | ||
| A tissue engineering approach to progenitor cell delivery results in significant cell engraftment and improved myocardial remodeling. | Q42688498 | ||
| Pharmacologically active microcarriers associated with thermosensitive hydrogel as a growth factor releasing biomimetic 3D scaffold for cardiac tissue-engineering | Q42799997 | ||
| Injectable intrathecal delivery system for localized administration of EGF and FGF-2 to the injured rat spinal cord | Q42814624 | ||
| Synthesis and characterization of Poloxamer 188-grafted heparin copolymer | Q43048909 | ||
| Temperature-induced gel formation of core/shell nanoparticles for the regeneration of ischemic heart | Q43086401 | ||
| Injectable, rapid gelling and highly flexible hydrogel composites as growth factor and cell carriers | Q43224443 | ||
| Stem cell-loaded nanofibrous patch promotes the regeneration of infarcted myocardium with functional improvement in rat model | Q43703890 | ||
| Myocardial cytokine expression in dogs with systemic and naturally occurring cardiac diseases. | Q44045377 | ||
| Surgical ventricular restoration with a cell- and cytokine-seeded biodegradable scaffold | Q44247957 | ||
| Sustained release of VEGF through PLGA microparticles improves vasculogenesis and tissue remodeling in an acute myocardial ischemia-reperfusion model. | Q45323473 | ||
| Phase I/IIa clinical trial of therapeutic angiogenesis using hepatocyte growth factor gene transfer to treat critical limb ischemia | Q45865836 | ||
| Regeneration of chronic myocardial infarction by injectable hydrogels containing stem cell homing factor SDF-1 and angiogenic peptide Ac-SDKP. | Q45973610 | ||
| VEGF improves survival of mesenchymal stem cells in infarcted hearts. | Q46031505 | ||
| The effects of peptide-based modification of alginate on left ventricular remodeling and function after myocardial infarction | Q46320512 | ||
| Biodegradable collagen patch with covalently immobilized VEGF for myocardial repair. | Q46367001 | ||
| P433 | issue | 5 | |
| P577 | publication date | 2017-03-10 | |
| P1433 | published in | Biotechnology Journal | Q15716480 |
| P1476 | title | Delivery of growth factor-based therapeutics in vascular diseases: Challenges and strategies | |
| P478 | volume | 12 |
Search more.